Cargando…

Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates

The potency and specificity of locked nucleic acid (LNA) antisense oligonucleotides was investigated as a function of length and affinity. The oligonucleotides were designed to target apolipoprotein B (apoB) and were investigated both in vitro and in vivo. The high affinity of LNA enabled the design...

Descripción completa

Detalles Bibliográficos
Autores principales:	Straarup, Ellen Marie, Fisker, Niels, Hedtjärn, Maj, Lindholm, Marie W., Rosenbohm, Christoph, Aarup, Vibeke, Hansen, Henrik Frydenlund, Ørum, Henrik, Hansen, Jens B. Rode, Koch, Troels
Formato:	Texto
Lenguaje:	English
Publicado:	Oxford University Press 2010
Materias:	Molecular Biology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2978335/ https://www.ncbi.nlm.nih.gov/pubmed/20615897 http://dx.doi.org/10.1093/nar/gkq457

Ejemplares similares

A Locked Nucleic Acid Antisense Oligonucleotide (LNA) Silences PCSK9 and Enhances LDLR Expression In Vitro and In Vivo
por: Gupta, Nidhi, et al.
Publicado: (2010)

Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents
por: Stein, C. A., et al.
Publicado: (2010)

In vivo uptake of antisense oligonucleotide drugs predicted by ab initio quantum mechanical calculations
por: Hansen, Henrik Frydenlund, et al.
Publicado: (2021)

Nuclear and Cytoplasmatic Quantification of Unconjugated, Label-Free Locked Nucleic Acid Oligonucleotides
por: Pendergraff, Hannah, et al.
Publicado: (2020)

Chemical Diversity of Locked Nucleic Acid-Modified Antisense Oligonucleotides Allows Optimization of Pharmaceutical Properties
por: Papargyri, Natalia, et al.
Publicado: (2019)

Electronic Structures of LNA Phosphorothioate Oligonucleotides
por: Bohr, Henrik G., et al.
Publicado: (2017)

Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver
por: Elmén, Joacim, et al.
Publicado: (2008)

Sequence motifs associated with hepatotoxicity of locked nucleic acid—modified antisense oligonucleotides
por: Burdick, Andrew D., et al.
Publicado: (2014)

Allele-Selective Knockdown of MYH7 Using Antisense Oligonucleotides
por: Anderson, Brian R., et al.
Publicado: (2020)

Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals
por: Swayze, Eric E., et al.
Publicado: (2007)

Targeting murine alveolar macrophages by the intratracheal administration of locked nucleic acid containing antisense oligonucleotides
por: Uemura, Yasunori, et al.
Publicado: (2019)

Synthesis and biophysical properties of carbamate-locked nucleic acid (LNA) oligonucleotides with potential antisense applications
por: Thorpe, Cameron, et al.
Publicado: (2019)

Identification and characterization of a MAPT-targeting locked nucleic acid antisense oligonucleotide therapeutic for tauopathies
por: Easton, Amy, et al.
Publicado: (2022)

Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality
por: Elmén, Joacim, et al.
Publicado: (2005)

Ribonuclease H1-dependent hepatotoxicity caused by locked nucleic acid-modified gapmer antisense oligonucleotides
por: Kasuya, Takeshi, et al.
Publicado: (2016)

Alpha-l-Locked Nucleic Acid-Modified Antisense Oligonucleotides Induce Efficient Splice Modulation In Vitro
por: Raguraman, Prithi, et al.
Publicado: (2020)

A cytoplasmic pathway for gapmer antisense oligonucleotide-mediated gene silencing in mammalian cells
por: Castanotto, Daniela, et al.
Publicado: (2015)

Managing the sequence-specificity of antisense oligonucleotides in drug discovery
por: Hagedorn, Peter H., et al.
Publicado: (2017)

Down-modulation of cancer targets using locked nucleic acid (LNA)-based antisense oligonucleotides without transfection
por: Zhang, Y, et al.
Publicado: (2011)

Meal-Related Changes in Apolipoprotein Particles After Treatment With an Antisense Oligonucleotide to Apolipoprotein CIII
por: Brite, Brianna, et al.
Publicado: (2021)

In vitro inhibition of porcine reproductive and respiratory syndrome virus replication by short antisense oligonucleotides with locked nucleic acid modification
por: Zhu, Lingyun, et al.
Publicado: (2018)

The intratracheal administration of locked nucleic acid containing antisense oligonucleotides induced gene silencing and an immune-stimulatory effect in the murine lung
por: Uemura, Yasunori, et al.
Publicado: (2017)

Rational Design of Short Locked Nucleic Acid-Modified 2′-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro
por: Le, Bao T., et al.
Publicado: (2017)

Quantitative fluorescence imaging determines the absolute number of locked nucleic acid oligonucleotides needed for suppression of target gene expression
por: Buntz, Annette, et al.
Publicado: (2019)

Identifying and avoiding off-target effects of RNase H-dependent antisense oligonucleotides in mice
por: Hagedorn, Peter H, et al.
Publicado: (2018)

In vitro and in vivo properties of therapeutic oligonucleotides containing non-chiral 3′ and 5′ thiophosphate linkages
por: Duschmalé, Jörg, et al.
Publicado: (2020)

Intramuscular Evaluation of Chimeric Locked Nucleic Acid/2′OMethyl-Modified Antisense Oligonucleotides for Targeted Exon 23 Skipping in Mdx Mice
por: Georgiadou, Michaella, et al.
Publicado: (2021)

Silencing of microRNA-155 in mice during acute inflammatory response leads to derepression of c/ebp Beta and down-regulation of G-CSF
por: Worm, Jesper, et al.
Publicado: (2009)

Application of Locked Nucleic Acid Oligonucleotides for siRNA Preclinical Bioanalytics
por: Thayer, Mai B., et al.
Publicado: (2019)

Nucleic acid binding proteins affect the subcellular distribution of phosphorothioate antisense oligonucleotides
por: Bailey, Jeffrey K., et al.
Publicado: (2017)

Design and evaluation of locked nucleic acid-based splice-switching oligonucleotides in vitro
por: Shimo, Takenori, et al.
Publicado: (2014)

Drug discovery and development scheme for liver-targeting bridged nucleic acid antisense oligonucleotides
por: Wada, Fumito, et al.
Publicado: (2021)

Cell-permeable peptide nucleic acid antisense oligonucleotide platform targeting human betacoronaviruses
por: Park, Soree, et al.
Publicado: (2023)

RNA Interference-Guided Targeting of Hepatitis C Virus Replication with Antisense Locked Nucleic Acid-Based Oligonucleotides Containing 8-oxo-dG Modifications
por: Mutso, Margit, et al.
Publicado: (2015)

Intracranial delivery of antisense locked nucleic acids for silencing microRNAs in the mouse brain
por: Sharma, Nikhil, et al.
Publicado: (2022)

Synthetic oligonucleotide antigens modified with locked nucleic acids detect disease specific antibodies
por: Samuelsen, Simone V., et al.
Publicado: (2016)

Volanesorsen, an Antisense Oligonucleotide to Apolipoprotein-CIII, Decreases Triglycerides and Increases Lipoprotein Lipase Activity in Partial Lipodystrophy
por: Lightbourne, Marissa, et al.
Publicado: (2021)

Liver-Targeted Anti-HBV Single-Stranded Oligonucleotides with Locked Nucleic Acid Potently Reduce HBV Gene Expression In Vivo
por: Javanbakht, Hassan, et al.
Publicado: (2018)

Design and In Vitro Evaluation of Splice-Switching Oligonucleotides Bearing Locked Nucleic Acids, Amido-Bridged Nucleic Acids, and Guanidine-Bridged Nucleic Acids
por: Shimo, Takenori, et al.
Publicado: (2021)

Antisense oligonucleotides in neurological disorders
por: Wurster, Claudia D., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_0ts1mt5j2g4egt6j0fao4ttdsg